MaxCyte Investor Presentation Deck

Continued Growth Over the Last 5+ Years 2022 2021 2020 2019 2018 2017 2022 2021 2020 2019 2018 2017 1 3 Core Business Revenue by Year $16M $13M $19M Core Business Revenue 8 $23M Cumulative SPL Partnerships by Year SPL Partnerships 12 $31M 15 18 20 $40M Core Revenue 5-Year CAGR ~25% 2018-2022 200+ Rapid Growth of Cumulative Instrument Placements 2017 250+ 2018 320+ M MaxCyte 2019 400+ Gross Margin ~89% 2018-2022 2020 500+ 2021 600+ 2022 © 2023 MaxCyte, Inc. All Rights Reserved

View entire presentation